Combined with basal breast cancer markers CK 6 and Vimentin, the MAPK-signaling protein Erk1/2- pThr202/Tyr204 and the active mTOR signaling protein eIF4E-pSer209, these proteins could differentiate PAB resistant from PAB sensitive BC-PDMs (Fig. 6M, Mann Whitney U-test, ***p < 0.001). This evidence concerns the gene MTOR and breast carcinoma.